

MÉDICA (BUY, T.P. MXN\$70.0)

Appoints new CFO and Legal Counsel

MÉDICA announced the appointment of Mr. Juan Francisco Ahedo Rozada as its new CFO as of July 1st. Mr. Ahedo is an industrial engineer who graduated with academic excellence from the Universidad Iberoamericana and has an MBA from Boston College in the United States. He has held senior management positions in several financial companies, including CREZE (credits to SMEs), CONTIGO (microfinance) and REV WORLDWIDE (payment processing).

On the other hand, MÉDICA announced the appointment of Mr. Moisés Francisco José Ramos González as Legal Counsel. Mr. Ramos González has a Bachelor's Degree in Law from the Universidad Iberoamericana with various diplomas and courses. He has a track record of more than seven years at MÉDICA'S legal areas and strategic projects.

We believe such appointments will strengthen MÉDICA's operating and financial performance. Our recommendation is BUY with MXN\$70.0/share target price.

July1st, 2024

Martin Lara
+5255-64138563
martin.lara@miranda-gr.com

DISCLAIMER

The current report was prepared by Miranda Global Research ("Miranda GR") for Vector Casa de Bolsa, S.A. de C.V. The information is presented in summarized form and is not meant to be complete. There are no declarations or guarantees, expressed or implicit, with respect to the accuracy, impartiality, or integrity of the information.

Miranda GR, in accordance with applicable legislation, has made sure that the presented personalized recommendation is reasonable to the client, as it has verified congruency between the client's profile and the profile of the financial product. Under no circumstance should it be understood that the fulfillment of the previously mentioned recommendation, guarantees the result or the success of the proposed strategies in the presented document.

The information included in this report was obtained from public sources. Projections or previsions included in this report, are a generalized recommendation and are based on subjective assumptions and estimations about events and circumstances that have not yet happened and are subjected to significant variations. Therefore, it is not possible to guarantee that any of the results included in the current report will happen in the future, in other words, it does not guarantee the result or the success of the posed strategies.

This report has been prepared solely for informational purposes. No declarations are made regarding precision, sufficiency, veracity, or accuracy of the information and opinions hereby included. Miranda GR will not answer (either because of negligence or for any other reason) for any damage or detriment derived or related to the use of this report or its content, or any connection to the report. Miranda GR is not responsible for the use or association with this report, including but not limited to, any declaration, expressed or implicit, or guarantees or omissions included in this information.

This report is based on facts and/or events that have happened up to this date. Consequently, any future facts and/or events can impair the conclusions hereby expressed. Miranda GR does not assume any responsibility to update, review, rectify or invalidate this report based on any future occurrence.

The opinions related to this report eventually expressed by Miranda GR, should be considered only as suggestions/recommendations to better operate various topics related to the report.

This report and its contents are the property of Miranda GR and cannot be reproduced or broadcast in part or in its entirety without the previous written consent of Miranda GR.

Miranda Global Research receives fees from Médica Sur, S.A.B. de C.V. for independent analyst services. Companies or Fibras under coverage will have no right or opportunity to exert any influence on opinions, projections, recommendations, and/or target prices expressed hereby by Miranda GR.
